US FDA approves Alembic Pharmaceuticals' fungal infection capsules
Perspectivas América Latina 2023 Emerging Trends & Growth
Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Alembic Pharmaceuticals Ltd. said the U.S. FDA approved its abbreviated new drug application for 100-milligram itraconazole capsules for the treatment of fungal infections including blastomycosis, histoplasmosis and aspergillosis.
The approved drug is therapeutically equivalent to Janssen Pharmaceuticals' Sporanox capsules.
